BPC-157 — the abbreviation stands for Body Protection Compound 157 — is a synthetic pentadecapeptide (15 amino acids) originally derived from a partial sequence of a larger cytoprotective compound identified in human gastric juice. It has been the subject of extensive preclinical research since the 1990s, primarily in animal models, and remains an active area of investigation in the peer-reviewed literature.
What BPC-157 is
BPC-157 is a chemically synthesised peptide consisting of 15 amino acid residues. It is not a naturally occurring biological product in the form supplied for research — it is a defined synthetic sequence produced by solid-phase peptide synthesis. Its parent compound was originally described in the context of gastroprotective research at the University of Zagreb, in a research programme associated with Predrag Sikirić and colleagues.
Molecular information
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV in one-letter code)
- Number of residues: 15
- Approximate monoisotopic mass: ~1419 Da (as the free acid; commercial preparations may vary in salt form, e.g. acetate, which affects the mass observed by LC-MS)
- Physical form: Typically supplied as a white lyophilised powder
The sequence is well characterised in the published literature and is the reference against which mass-spectrometry results should be compared during analytical verification.
Areas of published research
BPC-157 has been the subject of preclinical research across several domains in animal and in-vitro models, including:
- Gastrointestinal research — the peptide has been studied in rodent models of gastric and intestinal injury, in continuation of the gastric-juice cytoprotective research programme that originally identified it.
- Musculoskeletal research — studies in animal models have investigated the peptide's effects on tendon, ligament and skeletal-muscle injury repair.
- Angiogenesis and vascular research — the peptide has been investigated in relation to microvascular responses following tissue injury in rodent models.
- Neuroprotection and central-nervous-system research — animal studies have examined effects on nerve injury, cerebral ischaemia models and related contexts.
These research areas are represented in publications indexed on PubMed and in a range of peer-reviewed journals. The literature is predominantly preclinical (animal and in-vitro).
Research history and current interest
BPC-157 emerged from research into cytoprotective compounds in gastric juice conducted from the 1990s onwards. It has since attracted continued academic interest, particularly in the context of tissue-repair mechanisms and vascular responses. As of the current period, published human clinical data on BPC-157 are limited — the great majority of the literature consists of preclinical work in animal and cell-based systems. Researchers reviewing the field should distinguish between preclinical evidence and any inferences about human effects, which remain a subject of ongoing investigation and are not established.
Analytical considerations
For laboratory-based work with BPC-157, standard analytical checks apply:
- Identity by mass spectrometry. The observed molecular mass should be compared to the theoretical mass calculated from the 15-residue sequence. Modest discrepancies may indicate salt-form differences, oxidation of susceptible residues, or synthesis-related side products.
- Purity by HPLC. Reversed-phase HPLC with UV detection at 214 nm is the standard method. Purity is calculated by peak-area normalisation, as discussed in what is HPLC peptide testing.
- Batch documentation. A batch-specific Certificate of Analysis linking the peptide to a defined lot number is essential for reproducibility. See how to read a peptide COA.
- Solubility and reconstitution. BPC-157 is generally soluble in aqueous solutions; specific reconstitution behaviour depends on the salt form and concentration used.
Further reading
For peer-reviewed literature, PubMed is the primary index of published research on BPC-157. Searches on the term "BPC-157" return a range of preclinical studies across gastrointestinal, musculoskeletal, vascular and neuroprotective research areas. Readers are encouraged to evaluate primary sources directly rather than relying on secondary summaries.
Research Use Only. This profile is an educational overview of BPC-157 as a research peptide. It does not describe or recommend human, veterinary or clinical use. Peptovia Research supplies BPC-157 for strictly for in-vitro laboratory research. No dosing, administration or therapeutic guidance is provided or implied.